AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is a two-arm, open, multicenter clinical study to evaluate the efficacy and safety of
AK104 alone or in combination with cisplatin and paclitaxel in the treatment of advanced
esophageal squamous carcinoma without systemic therapy.